Distribution of pathogens and antimicrobial resistance in ICU-bloodstream infections during hospitalization: a nationwide surveillance study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 08 2021
Historique:
received: 23 06 2021
accepted: 28 07 2021
entrez: 20 8 2021
pubmed: 21 8 2021
medline: 11 11 2021
Statut: epublish

Résumé

Changing microorganism distributions and decreasing antibiotic susceptibility over the duration of hospitalization have been described for the colonization or infection of selected organ systems. Few data are available on bacteremias in the intensive care unit (ICU) setting. We conducted a nationwide study on bloodstream infection (BSI) using data from the Swiss Centre for Antibiotic Resistance (ANRESIS). We analyzed data on BSI detected in the ICU from hospitals that sent information on a regular basis during the entire study period (2008-2017). We described specific trends of pathogen distribution and resistance during hospitalization duration. We included 6505 ICU- BSI isolates from 35 Swiss hospitals. We observed 2587 possible skin contaminants, 3788 bacteremias and 130 fungemias. The most common microorganism was Escherichia coli (23.2%, 910), followed by Staphylococcus aureus (18.7%, 734) and enterococci (13.1%, 515). Enterococcus spp (p < 0.0001) and Candida spp (p < 0.0001) increased in proportion, whereas E. coli (p < 0.0001) and S. aureus (p < 0.0001) proportions decreased during hospitalization. Resistances against first- and second-line antibiotics increased linearly during hospitalization. Pathogen distribution and antimicrobial resistance in ICU-BSI depends on the duration of the hospitalization. The proportion of enterococcal BSI, candidemia and resistant microorganisms against first- and second-line antibiotics increased during hospitalization.

Identifiants

pubmed: 34413340
doi: 10.1038/s41598-021-95873-z
pii: 10.1038/s41598-021-95873-z
pmc: PMC8376881
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16876

Informations de copyright

© 2021. The Author(s).

Références

Am J Infect Control. 2015 Nov;43(11):1222-37
pubmed: 26298636
N Engl J Med. 2010 May 13;362(19):1804-13
pubmed: 20463340
J Antimicrob Chemother. 2008 Dec;62(6):1451-61
pubmed: 18776189
Clin Microbiol Rev. 2014 Oct;27(4):647-64
pubmed: 25278570
Infect Control Hosp Epidemiol. 2013 Oct;34(10):1042-7
pubmed: 24018920
J Hosp Infect. 2017 May;96(1):35-41
pubmed: 28359546
Clin Microbiol Infect. 2021 Apr 30;:
pubmed: 33933567
Clin Microbiol Rev. 2019 Oct 30;33(1):
pubmed: 31666280
Infect Control Hosp Epidemiol. 2010 Apr;31(4):388-94
pubmed: 20156064
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
J Hosp Infect. 2000 Jan;44(1):31-6
pubmed: 10633051
Intensive Care Med. 2012 Dec;38(12):1930-45
pubmed: 23011531
Clin Microbiol Infect. 2018 Jan;24(1):45-52
pubmed: 28559001

Auteurs

Rami Sommerstein (R)

Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland. rami.sommerstein@hirslanden.ch.

Lauro Damonti (L)

Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland.

Jonas Marschall (J)

Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland.

Stephan Harbarth (S)

Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Michael Gasser (M)

Swiss Centre for Antibiotic Resistance (ANRESIS), Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

Andreas Kronenberg (A)

Swiss Centre for Antibiotic Resistance (ANRESIS), Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

Niccolò Buetti (N)

Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland. niccolo.buetti@gmail.com.
INSERM, IAME, University of Paris, Paris, France. niccolo.buetti@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH